What the AstraZeneca and Ranbaxy Pay-to-Delay Case Didn’t Tell Us – Pharmalot – WSJ
0
A closely watched trial that many hoped would help clarify a contentious battle over access to generic drugs instead ended in disappointment last week. In fact, the outcome only seems to have underscored the difficulty in sorting out so-called pay-to-delay deals, a topic that has embroiled the pharmaceutical industry, regulators and the courts for years.
Read more – Pharmalot – WSJ